These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17609586)

  • 21. Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.
    Peng M; Huang Y; Tao T; Peng CY; Su Q; Xu W; Darko KO; Tao X; Yang X
    Sci Rep; 2016 Jun; 6():28611. PubMed ID: 27334428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis.
    Munk M; Memon AA; Nexo E; Sorensen BS
    BJU Int; 2007 Jan; 99(1):196-201. PubMed ID: 17092291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
    Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of EGFR-directed therapy in the treatment of breast cancer.
    Morris C
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S51-5; discussion S57-9. PubMed ID: 12353824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.
    Li J; Kleeff J; Giese N; Büchler MW; Korc M; Friess H
    Int J Oncol; 2004 Jul; 25(1):203-10. PubMed ID: 15202007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
    Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
    Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular correlates of gefitinib responsiveness in human bladder cancer cells.
    Shrader M; Pino MS; Brown G; Black P; Adam L; Bar-Eli M; Dinney CP; McConkey DJ
    Mol Cancer Ther; 2007 Jan; 6(1):277-85. PubMed ID: 17237287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
    Flaig TW; Su LJ; McCoach C; Li Y; Raben D; Varella-Garcia M; Bemis LT
    BJU Int; 2009 Jun; 103(12):1729-37. PubMed ID: 19220256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
    Hidalgo M; Amador ML; Jimeno A; Mezzadra H; Patel P; Chan A; Nielsen ME; Maitra A; Altiok S
    Mol Cancer Ther; 2006 Jul; 5(7):1895-903. PubMed ID: 16891476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
    Suzuki T; Nakagawa T; Endo H; Mitsudomi T; Masuda A; Yatabe Y; Sugiura T; Takahashi T; Hida T
    Lung Cancer; 2003 Oct; 42(1):35-41. PubMed ID: 14512185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
    Bonaccorsi L; Marchiani S; Muratori M; Forti G; Baldi E
    J Cancer Res Clin Oncol; 2004 Oct; 130(10):604-14. PubMed ID: 15258753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').
    Stea B; Falsey R; Kislin K; Patel J; Glanzberg H; Carey S; Ambrad AA; Meuillet EJ; Martinez JD
    Cancer Lett; 2003 Dec; 202(1):43-51. PubMed ID: 14643025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.
    Kassouf W; Luongo T; Brown G; Adam L; Dinney CP
    J Urol; 2006 Aug; 176(2):787-92. PubMed ID: 16813948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
    Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
    Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.